HZOMarineMax, Inc.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though modest expectations priced in.
Priced for a decline (~−10% a year). Little growth is priced in even as revenue fell 2% a year over three years, potential value, or a value trap.
In its normal range: P/E 8.8 vs a 9.3 median over 36 quarters (−5% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What HZO's price assumes
MarineMax, Inc. trades at 403× earnings against 19.5× for the median Specialty Retail name, more expensive than its own group.
Trailing P/E · Specialty Retail median 19.5 · 20.7× the median: the market pays up for this one
- Free cash flow yield
- 15%
Free cash flow yield · Specialty Retail median 5.8%
- Growth the price implies
- −9.7%
Growth the price implies · The price pays for −9.7% free cash flow growth a year for a decade; revenue has grown −2.1% a year over the last three.
Details›
- Consumer Cyclical median P/E321 names
- 17.9
- Specialty Retail median P/E25 names
- 19.5
- Free cash flow, trailing twelve months
- $178M
- Market capitalisation
- $1.15B
- 3-year revenue growth
- −2.1%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $0.97 |
| Its own P/E history, median | $1.21 |
| Its own P/E history, upper quartile | $1.83 |
| 52-week range | $21.43 – $52.50 |
| Today | $52.43 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.